Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 11 2021
03 11 2021
Historique:
received:
24
05
2021
accepted:
12
10
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Sparse data exist on the complex natural immunity to SARS-CoV-2 at the population level. We applied a well-validated multiplex serology test in 5000 participants of a general population study in Catalonia in blood samples collected from end June to mid November 2020. Based on responses to fifteen isotype-antigen combinations, we detected a seroprevalence of 18.1% in adults (n = 4740), and modeled extrapolation to the general population of Catalonia indicated a 15.3% seroprevalence. Antibodies persisted up to 9 months after infection. Immune profiling of infected individuals revealed that with increasing severity of infection (asymptomatic, 1-3 symptoms, ≥ 4 symptoms, admitted to hospital/ICU), seroresponses were more robust and rich with a shift towards IgG over IgA and anti-spike over anti-nucleocapsid responses. Among seropositive participants, lower antibody levels were observed for those ≥ 60 years vs < 60 years old and smokers vs non-smokers. Overweight/obese participants vs normal weight had higher antibody levels. Adolescents (13-15 years old) (n = 260) showed a seroprevalence of 11.5%, were less likely to be tested seropositive compared to their parents and had dominant anti-spike rather than anti-nucleocapsid IgG responses. Our study provides an unbiased estimate of SARS-CoV-2 seroprevalence in Catalonia and new evidence on the durability and heterogeneity of post-infection immunity.
Identifiants
pubmed: 34732749
doi: 10.1038/s41598-021-00807-4
pii: 10.1038/s41598-021-00807-4
pmc: PMC8566562
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21571Informations de copyright
© 2021. The Author(s).
Références
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Cochrane Database Syst Rev. 2021 Feb 23;2:CD013665
pubmed: 33620086
Nat Commun. 2021 Feb 2;12(1):740
pubmed: 33531472
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Lancet Microbe. 2021 Feb;2(2):e60-e69
pubmed: 33521709
EBioMedicine. 2021 Mar;65:103259
pubmed: 33662833
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
J Biol Regul Homeost Agents. 2020 Apr 07;34(2):339-343
pubmed: 32253888
Int J Epidemiol. 2012 Aug;41(4):930-40
pubmed: 21471022
BMC Public Health. 2019 Aug 16;19(1):1122
pubmed: 31420029
BMJ Open. 2018 Mar 27;8(3):e018324
pubmed: 29593016
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32398307
Lancet Child Adolesc Health. 2020 Jun;4(6):414-416
pubmed: 32458804
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2025-e2034
pubmed: 33524125
Lancet. 2020 Sep 5;396(10252):e24
pubmed: 32861312
Lancet Infect Dis. 2021 May;21(5):617-628
pubmed: 33476567
N Engl J Med. 2020 Oct 29;383(18):1782-1784
pubmed: 32871061
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Transl Res. 2021 Jun;232:60-74
pubmed: 33582244
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
PLoS One. 2020 May 11;15(5):e0233147
pubmed: 32392262
Nat Med. 2021 Mar;27(3):454-462
pubmed: 33589825
Emerg Microbes Infect. 2020 Dec;9(1):1965-1973
pubmed: 32819220
Nat Rev Immunol. 2020 Apr;20(4):229-238
pubmed: 31836872
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
BMJ. 2020 Sep 3;370:m3364
pubmed: 32883673
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
Am J Epidemiol. 2015 Sep 15;182(6):544-56
pubmed: 26306665
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
J Infect Dis. 2021 Jan 4;223(1):62-71
pubmed: 33175145
Lancet Glob Health. 2021 May;9(5):e598-e609
pubmed: 33705690
J Clin Med. 2020 Dec 09;9(12):
pubmed: 33317059
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Eur Respir J. 1994 May;7(5):954-60
pubmed: 8050554
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
PLoS One. 2020 Nov 3;15(11):e0241536
pubmed: 33141862
JAMA. 2021 Oct 12;326(14):1400-1409
pubmed: 34473201
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33127841
JAMA Intern Med. 2021 May 1;181(5):672-679
pubmed: 33625463
Pediatrics. 1968 Mar;41(3):600-11
pubmed: 4171004
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680
mBio. 2021 Jan 19;12(1):
pubmed: 33468695
Clin Biochem. 2021 Nov;97:54-61
pubmed: 34453893
Cell Rep Med. 2021 Feb 16;2(2):100191
pubmed: 33521694